Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says
By Emilie Ruscoe · March 9, 2026, 6:40 PM EDT
Brass of Ultragenyx Pharmaceutical Inc. are facing shareholder derivative claims they caused the company to overstate prospects for a drug to treat a bone disease, hurting investors and opening the company...
To view the full article, register now.